Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb.
Source link
Trending
- Australia Day Protesters Vandalize Melbourne and Sydney Statues
- North Korea fires strategic cruise missiles, vows tough stance on U.S.
- New Leaders in Lebanon Face Test as Israel Is Poised to Keep Troops There
- India, a Big Source of Illegal Migration, Hopes to Navigate the Trump Storm
- His Opponents Sidelined, Lukashenko Is Set for a 7th Term in Belarus
- Israel Welcomes the Return of the Women Who Warned of a Raid From Gaza
- Quebec’s Ban on Religious Symbols Will Be Tested at the Supreme Court
- What to Know About the 4 Newly Released Israeli Hostages
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
